Quest Diagnostics (NYSE: DGX ) reported earnings on July 19. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Quest Diagnostics missed slightly on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share expanded.
Gross margins shrank, operating margins dropped, net margins increased.
Quest Diagnostics booked revenue of $1.91 billion. The 19 analysts polled by S&P Capital IQ predicted revenue of $1.94 billion on the same basis. GAAP reported sales were 0.2% higher than the prior-year quarter's $1.90 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.17. The 22 earnings estimates compiled by S&P Capital IQ predicted $1.17 per share. GAAP EPS of $1.11 for Q2 were 8.8% higher than the prior-year quarter's $1.02 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 41.8%, 20 basis points worse than the prior-year quarter. Operating margin was 17.6%, 10 basis points worse than the prior-year quarter. Net margin was 9.3%, 70 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.92 billion. On the bottom line, the average EPS estimate is $1.19.
Next year's average estimate for revenue is $7.68 billion. The average EPS estimate is $4.57.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 546 members out of 578 rating the stock outperform, and 33 members rating it underperform. Among 174 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 167 give Quest Diagnostics a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quest Diagnostics is hold, with an average price target of $62.63.
- Add Quest Diagnostics to My Watchlist.